EMEA (Europe, Middle East and Africa) Nanostructured Drug Market Report 2017

October 2017 | 120 pages | ID: EEA36B09F0CWEN
QYResearch

Abstracts

In this report, the EMEA Nanostructured Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Doses), revenue (Million USD), market share and growth rate of Nanostructured Drug for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Nanostructured Drug market competition by top manufacturers/players, with Nanostructured Drug sales volume (K Doses), price (USD/Dose), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Merck
• Pfizer
• Novartis
• Abbott
• GlaxoSmithKline
• Roche
• Sanofi
• Eli Lilly
• Astrazeneca
• Johnson & Johnson
• Celgene
• Novavax
• Stryker
• Gilead Sciences
• OSI Pharmaceuticals
• Kadmon Pharmaceuticals
• Samyang Biopharm
• Mitsubishi Pharma
• Kaken Pharmaceutical
• Selecta Biosciences
• Par Pharmaceutical
• Cerulean Pharma
• Navidea Biopharmaceuticals
• Lummy

On the basis of product, this report displays the sales volume (K Doses), revenue (Million USD), product price (USD/Dose), market share and growth rate of each type, primarily split into

• Liposomes
• Polymeric Micelles
• Solid lipid Nanoparticles
• Microemulsion and Nanoemulsion
• Nanosuspension

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (K Doses), market share and growth rate of Nanostructured Drug for each application, including

• Cancer and Tumors
• Autoimmune Disorders

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) Nanostructured Drug Market Report 2017

1 NANOSTRUCTURED DRUG OVERVIEW

1.1 Product Overview and Scope of Nanostructured Drug
1.2 Classification of Nanostructured Drug
  1.2.1 EMEA Nanostructured Drug Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA Nanostructured Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Liposomes
  1.2.4 Polymeric Micelles
  1.2.5 Solid lipid Nanoparticles
  1.2.6 Microemulsion and Nanoemulsion
  1.2.7 Nanosuspension
1.3 EMEA Nanostructured Drug Market by Application/End Users
  1.3.1 EMEA Nanostructured Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Cancer and Tumors
  1.3.3 Autoimmune Disorders
1.4 EMEA Nanostructured Drug Market by Region
  1.4.1 EMEA Nanostructured Drug Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Nanostructured Drug (2012-2022)
  1.5.1 EMEA Nanostructured Drug Sales and Growth Rate (2012-2022)
  1.5.2 EMEA Nanostructured Drug Revenue and Growth Rate (2012-2022)

2 EMEA NANOSTRUCTURED DRUG COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA Nanostructured Drug Market Competition by Players/Manufacturers
  2.1.1 EMEA Nanostructured Drug Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA Nanostructured Drug Revenue and Share by Players (2012-2017)
  2.1.3 EMEA Nanostructured Drug Sale Price by Players (2012-2017)
2.2 EMEA Nanostructured Drug (Volume and Value) by Type/Product Category
  2.2.1 EMEA Nanostructured Drug Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA Nanostructured Drug Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA Nanostructured Drug Sale Price by Type (2012-2017)
2.3 EMEA Nanostructured Drug (Volume) by Application
2.4 EMEA Nanostructured Drug (Volume and Value) by Region
  2.4.1 EMEA Nanostructured Drug Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA Nanostructured Drug Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA Nanostructured Drug Sales Price by Region (2012-2017)

3 EUROPE NANOSTRUCTURED DRUG (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe Nanostructured Drug Sales and Value (2012-2017)
  3.1.1 Europe Nanostructured Drug Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe Nanostructured Drug Revenue and Growth Rate (2012-2017)
3.2 Europe Nanostructured Drug Sales and Market Share by Type
3.3 Europe Nanostructured Drug Sales and Market Share by Application
3.4 Europe Nanostructured Drug Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe Nanostructured Drug Sales Volume by Countries (2012-2017)
  3.4.2 Europe Nanostructured Drug Revenue by Countries (2012-2017)
  3.4.3 Germany Nanostructured Drug Sales and Growth Rate (2012-2017)
  3.4.4 France Nanostructured Drug Sales and Growth Rate (2012-2017)
  3.4.5 UK Nanostructured Drug Sales and Growth Rate (2012-2017)
  3.4.6 Russia Nanostructured Drug Sales and Growth Rate (2012-2017)
  3.4.7 Italy Nanostructured Drug Sales and Growth Rate (2012-2017)
  3.4.8 Benelux Nanostructured Drug Sales and Growth Rate (2012-2017)

4 MIDDLE EAST NANOSTRUCTURED DRUG (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East Nanostructured Drug Sales and Value (2012-2017)
  4.1.1 Middle East Nanostructured Drug Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East Nanostructured Drug Revenue and Growth Rate (2012-2017)
4.2 Middle East Nanostructured Drug Sales and Market Share by Type
4.3 Middle East Nanostructured Drug Sales and Market Share by Application
4.4 Middle East Nanostructured Drug Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East Nanostructured Drug Sales Volume by Countries (2012-2017)
  4.4.2 Middle East Nanostructured Drug Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia Nanostructured Drug Sales and Growth Rate (2012-2017)
  4.4.4 Israel Nanostructured Drug Sales and Growth Rate (2012-2017)
  4.4.5 UAE Nanostructured Drug Sales and Growth Rate (2012-2017)
  4.4.6 Iran Nanostructured Drug Sales and Growth Rate (2012-2017)

5 AFRICA NANOSTRUCTURED DRUG (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa Nanostructured Drug Sales and Value (2012-2017)
  5.1.1 Africa Nanostructured Drug Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa Nanostructured Drug Revenue and Growth Rate (2012-2017)
5.2 Africa Nanostructured Drug Sales and Market Share by Type
5.3 Africa Nanostructured Drug Sales and Market Share by Application
5.4 Africa Nanostructured Drug Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa Nanostructured Drug Sales Volume by Countries (2012-2017)
  5.4.2 Africa Nanostructured Drug Revenue by Countries (2012-2017)
  5.4.3 South Africa Nanostructured Drug Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria Nanostructured Drug Sales and Growth Rate (2012-2017)
  5.4.5 Egypt Nanostructured Drug Sales and Growth Rate (2012-2017)
  5.4.6 Algeria Nanostructured Drug Sales and Growth Rate (2012-2017)

6 EMEA NANOSTRUCTURED DRUG MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Merck
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 Nanostructured Drug Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Merck Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Pfizer
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 Nanostructured Drug Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Pfizer Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Novartis
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 Nanostructured Drug Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Novartis Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Abbott
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 Nanostructured Drug Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Abbott Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 GlaxoSmithKline
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 Nanostructured Drug Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 GlaxoSmithKline Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Roche
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 Nanostructured Drug Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Roche Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Sanofi
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 Nanostructured Drug Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Sanofi Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Eli Lilly
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 Nanostructured Drug Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Eli Lilly Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Astrazeneca
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 Nanostructured Drug Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Astrazeneca Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Johnson & Johnson
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 Nanostructured Drug Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Johnson & Johnson Nanostructured Drug Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Celgene
6.12 Novavax
6.13 Stryker
6.14 Gilead Sciences
6.15 OSI Pharmaceuticals
6.16 Kadmon Pharmaceuticals
6.17 Samyang Biopharm
6.18 Mitsubishi Pharma
6.19 Kaken Pharmaceutical
6.20 Selecta Biosciences
6.21 Par Pharmaceutical
6.22 Cerulean Pharma
6.23 Navidea Biopharmaceuticals
6.24 Lummy

7 NANOSTRUCTURED DRUG MANUFACTURING COST ANALYSIS

7.1 Nanostructured Drug Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Nanostructured Drug

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 Nanostructured Drug Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Nanostructured Drug Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA NANOSTRUCTURED DRUG MARKET FORECAST (2017-2022)

11.1 EMEA Nanostructured Drug Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA Nanostructured Drug Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA Nanostructured Drug Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA Nanostructured Drug Price and Trend Forecast (2017-2022)
11.2 EMEA Nanostructured Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Nanostructured Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Nanostructured Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Nanostructured Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Nanostructured Drug Sales Forecast by Type (2017-2022)
11.7 EMEA Nanostructured Drug Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of Nanostructured Drug
Figure EMEA Nanostructured Drug Sales Volume (K Doses) by Type (2012-2022)
Figure EMEA Nanostructured Drug Sales Volume Market Share by Type (Product Category) in 2016
Figure Liposomes Product Picture
Figure Polymeric Micelles Product Picture
Figure Solid lipid Nanoparticles Product Picture
Figure Microemulsion and Nanoemulsion Product Picture
Figure Nanosuspension Product Picture
Figure EMEA Nanostructured Drug Sales Volume (K Doses) by Application (2012-2022)
Figure EMEA Sales Market Share of Nanostructured Drug by Application in 2016
Figure Cancer and Tumors Examples
Table Key Downstream Customer in Cancer and Tumors
Figure Autoimmune Disorders Examples
Table Key Downstream Customer in Autoimmune Disorders
Figure EMEA Nanostructured Drug Market Size (Million USD) by Region (2012-2022)
Figure Europe Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Nanostructured Drug Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Nanostructured Drug Revenue (Million USD) Status and Forecast by Countries
Figure Africa Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Nanostructured Drug Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Nanostructured Drug Sales Volume and Growth Rate (2012-2022)
Figure EMEA Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Nanostructured Drug Market Major Players Product Sales Volume (K Doses) (2012-2017)
Table EMEA Nanostructured Drug Sales Volume (K Doses) of Major Players (2012-2017)
Table EMEA Nanostructured Drug Sales Share by Players (2012-2017)
Figure 2016 Nanostructured Drug Sales Share by Players
Figure 2017 Nanostructured Drug Sales Share by Players
Figure EMEA Nanostructured Drug Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Nanostructured Drug Revenue (Million USD) by Players (2012-2017)
Table EMEA Nanostructured Drug Revenue Share by Players (2012-2017)
Table 2016 EMEA Nanostructured Drug Revenue Share by Players
Table 2017 EMEA Nanostructured Drug Revenue Share by Players
Table EMEA Nanostructured Drug Sale Price (USD/Dose) by Players (2012-2017)
Table EMEA Nanostructured Drug Sales (K Doses) and Market Share by Type (2012-2017)
Table EMEA Nanostructured Drug Sales Share by Type (2012-2017)
Figure Sales Market Share of Nanostructured Drug by Type (2012-2017)
Figure EMEA Nanostructured Drug Sales Market Share by Type (2012-2017)
Table EMEA Nanostructured Drug Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Nanostructured Drug Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Nanostructured Drug by Type in 2016
Table EMEA Nanostructured Drug Sale Price (USD/Dose) by Type (2012-2017)
Table EMEA Nanostructured Drug Sales (K Doses) and Market Share by Application (2012-2017)
Table EMEA Nanostructured Drug Sales Share by Application (2012-2017)
Figure Sales Market Share of Nanostructured Drug by Application (2012-2017)
Figure EMEA Nanostructured Drug Sales Market Share by Application in 2016
Table EMEA Nanostructured Drug Sales (K Doses) and Market Share by Region (2012-2017)
Table EMEA Nanostructured Drug Sales Share by Region (2012-2017)
Figure Sales Market Share of Nanostructured Drug by Region (2012-2017)
Figure EMEA Nanostructured Drug Sales Market Share in 2016
Table EMEA Nanostructured Drug Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Nanostructured Drug Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Nanostructured Drug by Region (2012-2017)
Figure EMEA Nanostructured Drug Revenue Market Share Regions in 2016
Table EMEA Nanostructured Drug Sales Price (USD/Dose) by Region (2012-2017)
Figure Europe Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Europe Nanostructured Drug Revenue and Growth Rate (2012-2017)
Table Europe Nanostructured Drug Sales (K Doses) by Type (2012-2017)
Table Europe Nanostructured Drug Market Share by Type (2012-2017)
Figure Europe Nanostructured Drug Market Share by Type in 2016
Table Europe Nanostructured Drug Sales (K Doses) by Application (2012-2017)
Table Europe Nanostructured Drug Market Share by Application (2012-2017)
Figure Europe Nanostructured Drug Market Share by Application in 2016
Table Europe Nanostructured Drug Sales (K Doses) by Countries (2012-2017)
Table Europe Nanostructured Drug Sales Market Share by Countries (2012-2017)
Figure Europe Nanostructured Drug Sales Market Share by Countries (2012-2017)
Figure Europe Nanostructured Drug Sales Market Share by Countries in 2016
Table Europe Nanostructured Drug Revenue (Million USD) by Countries (2012-2017)
Table Europe Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Europe Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Europe Nanostructured Drug Revenue Market Share by Countries in 2016
Figure Germany Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure France Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure UK Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Russia Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Italy Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Benelux Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Middle East Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Middle East Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Nanostructured Drug Sales (K Doses) by Type (2012-2017)
Table Middle East Nanostructured Drug Market Share by Type (2012-2017)
Figure Middle East Nanostructured Drug Market Share by Type (2012-2017)
Table Middle East Nanostructured Drug Sales (K Doses) by Applications (2012-2017)
Table Middle East Nanostructured Drug Market Share by Applications (2012-2017)
Figure Middle East Nanostructured Drug Sales Market Share by Application in 2016
Table Middle East Nanostructured Drug Sales Volume (K Doses) by Countries (2012-2017)
Table Middle East Nanostructured Drug Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Nanostructured Drug Sales Volume Market Share by Countries in 2016
Table Middle East Nanostructured Drug Revenue (Million USD) by Countries (2012-2017)
Table Middle East Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Middle East Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Middle East Nanostructured Drug Revenue Market Share by Countries in 2016
Figure Saudi Arabia Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Israel Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure UAE Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Iran Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Africa Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Africa Nanostructured Drug Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Nanostructured Drug Sales (K Doses) by Type (2012-2017)
Table Africa Nanostructured Drug Sales Market Share by Type (2012-2017)
Figure Africa Nanostructured Drug Sales Market Share by Type (2012-2017)
Figure Africa Nanostructured Drug Sales Market Share by Type in 2016
Table Africa Nanostructured Drug Sales (K Doses) by Application (2012-2017)
Table Africa Nanostructured Drug Sales Market Share by Application (2012-2017)
Figure Africa Nanostructured Drug Sales Market Share by Application (2012-2017)
Table Africa Nanostructured Drug Sales Volume (K Doses) by Countries (2012-2017)
Table Africa Nanostructured Drug Sales Market Share by Countries (2012-2017)
Figure Africa Nanostructured Drug Sales Market Share by Countries (2012-2017)
Figure Africa Nanostructured Drug Sales Market Share by Countries in 2016
Table Africa Nanostructured Drug Revenue (Million USD) by Countries (2012-2017)
Table Africa Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Africa Nanostructured Drug Revenue Market Share by Countries (2012-2017)
Figure Africa Nanostructured Drug Revenue Market Share by Countries in 2016
Figure South Africa Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Nigeria Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Egypt Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Algeria Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Table Merck Nanostructured Drug Basic Information List
Table Merck Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Merck Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Merck Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Merck Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Pfizer Nanostructured Drug Basic Information List
Table Pfizer Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Pfizer Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Pfizer Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Pfizer Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Novartis Nanostructured Drug Basic Information List
Table Novartis Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Novartis Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Novartis Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Novartis Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Abbott Nanostructured Drug Basic Information List
Table Abbott Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Abbott Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Abbott Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Abbott Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table GlaxoSmithKline Nanostructured Drug Basic Information List
Table GlaxoSmithKline Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure GlaxoSmithKline Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure GlaxoSmithKline Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure GlaxoSmithKline Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Roche Nanostructured Drug Basic Information List
Table Roche Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Roche Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Roche Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Roche Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Sanofi Nanostructured Drug Basic Information List
Table Sanofi Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Sanofi Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Sanofi Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Sanofi Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Eli Lilly Nanostructured Drug Basic Information List
Table Eli Lilly Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Eli Lilly Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Eli Lilly Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Eli Lilly Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Astrazeneca Nanostructured Drug Basic Information List
Table Astrazeneca Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Astrazeneca Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Astrazeneca Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Astrazeneca Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Johnson & Johnson Nanostructured Drug Basic Information List
Table Johnson & Johnson Nanostructured Drug Sales (K Doses), Revenue (Million USD), Price (USD/Dose) and Gross Margin (2012-2017)
Figure Johnson & Johnson Nanostructured Drug Sales (K Doses) and Growth Rate (2012-2017)
Figure Johnson & Johnson Nanostructured Drug Sales Market Share in EMEA (2012-2017)
Figure Johnson & Johnson Nanostructured Drug Revenue Market Share in EMEA (2012-2017)
Table Celgene Nanostructured Drug Basic Information List
Table Novavax Nanostructured Drug Basic Information List
Table Stryker Nanostructured Drug Basic Information List
Table Gilead Sciences Nanostructured Drug Basic Information List
Table OSI Pharmaceuticals Nanostructured Drug Basic Information List
Table Kadmon Pharmaceuticals Nanostructured Drug Basic Information List
Table Samyang Biopharm Nanostructured Drug Basic Information List
Table Mitsubishi Pharma Nanostructured Drug Basic Information List
Table Kaken Pharmaceutical Nanostructured Drug Basic Information List
Table Selecta Biosciences Nanostructured Drug Basic Information List
Table Par Pharmaceutical Nanostructured Drug Basic Information List
Table Cerulean Pharma Nanostructured Drug Basic Information List
Table Navidea Biopharmaceuticals Nanostructured Drug Basic Information List
Table Lummy Nanostructured Drug Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Nanostructured Drug
Figure Manufacturing Process Analysis of Nanostructured Drug
Figure Nanostructured Drug Industrial Chain Analysis
Table Raw Materials Sources of Nanostructured Drug Major Manufacturers in 2016
Table Major Buyers of Nanostructured Drug
Table Distributors/Traders List
Figure EMEA Nanostructured Drug Sales (K Doses) and Growth Rate Forecast (2017-2022)
Figure EMEA Nanostructured Drug Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Nanostructured Drug Price (USD/Dose) and Trend Forecast (2017-2022)
Table EMEA Nanostructured Drug Sales (K Doses) Forecast by Region (2017-2022)
Figure EMEA Nanostructured Drug Sales Market Share Forecast by Region (2017-2022)
Table EMEA Nanostructured Drug Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Nanostructured Drug Revenue Market Share Forecast by Region (2017-2022)
Table Europe Nanostructured Drug Sales (K Doses) Forecast by Countries (2017-2022)
Figure Europe Nanostructured Drug Sales Market Share Forecast by Countries (2017-2022)
Table Europe Nanostructured Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Nanostructured Drug Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Nanostructured Drug Sales (K Doses) Forecast by Countries (2017-2022)
Figure Middle East Nanostructured Drug Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Nanostructured Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Nanostructured Drug Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Nanostructured Drug Sales (K Doses) Forecast by Countries (2017-2022)
Figure Africa Nanostructured Drug Sales Market Share Forecast by Countries (2017-2022)
Table Africa Nanostructured Drug Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Nanostructured Drug Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Nanostructured Drug Sales (K Doses) Forecast by Type (2017-2022)
Figure EMEA Nanostructured Drug Sales Market Share Forecast by Type (2017-2022)
Table EMEA Nanostructured Drug Sales (K Doses) Forecast by Application (2017-2022)
Figure EMEA Nanostructured Drug Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources